# 1) Receptor-level action → clinical effects
**Primary:** **GABA-A positive allosteric modulator (benzodiazepine class).**
* Binds at the **benzodiazepine site** (α/γ interface) → **increases the frequency** of Cl⁻ channel opening **in the presence of GABA** → neuronal hyperpolarisation.
* **No direct gating** (unlike propofol/barbiturates at high dose): requires GABA to be present.
**Other receptor effects (minor):**
* Weak inhibition of some **nicotinic ACh** and **5-HT3** currents reported; clinically trivial.
* **Central** effects dominate: anxiolysis, sedation/hypnosis, **anterograde amnesia**, anticonvulsant, mild muscle relaxation.
**Clinical effects that matter**
* **CNS:** dose-dependent sedation → hypnosis; **anterograde amnesia**; anticonvulsant (useful in status epilepticus).
* **CVS:** usually modest ↓MAP (venodilation/sympathetic blunting), but can be **pronounced in hypovolaemia/poor EF/with opioids**.
* **Respiratory:** dose-dependent depression; **synergistic** with opioids/propofol → apnoea risk.
* **Delirium:** prolonged infusions rise risk of ICU delirium; prefer light/targeted use.
---
# 2) Vial strength, preparation & basic pharmacokinetics (+ disadvantages)
**Formulation & vials**
* Water-soluble **imidazo-benzodiazepine**: ring **open** (water-soluble) in acidic vial; ring **closes** at physiologic pH → lipophilic & fast CNS entry.
* Common vials/amps: **1 mg/mL** (2 mL) and **5 mg/mL** (1–10 mL); ICU syringes often **50 mg/50 mL** or **100 mg/100 mL**.
**PK you’ll feel at the bedside**
* **Onset (IV):** 1–3 min; **peak:** 3–5 min; **single-dose duration:** ~30–60 min (redistribution).
* **Distribution:** large Vd (↑ with obesity/critical illness).
* **Metabolism:** hepatic **CYP3A4/5** → **1-hydroxymidazolam** (active), then glucuronidation.
* **Elimination:** renal excretion of metabolites.
* **Context-sensitive half-time:** short after a bolus but **rises steeply with infusion duration**, especially with **renal failure** (active metabolite accumulates).
**Practical disadvantages (stemming from above)**
* **Accumulation** with prolonged infusion/obesity/hepatic-renal dysfunction → delayed wake-up.
* **ICU delirium** risk > propofol/dex; avoid routine deep benzo sedation.
* **Drug–drug variability** (CYP3A inhibitors/inducers).
---
# 3) Practical dosing
## A. Theatre/Procedural use
* **Premed/anxiolysis (IV):** **1–2 mg** (0.02–0.04 mg/kg) titrated slowly.
* **Induction (rare as sole agent):** **0.1–0.3 mg/kg IV**—often **not ideal** due to slow, unpredictable hypnosis and haemodynamic depression when combined with opioids.
* **Adjunct to induction/maintenance:** small **0.5–2 mg** increments for amnesia.
## B. ICU sedation (avoid routine deep benzo sedation; use when indicated)
**Indications:** short-term bridge when propofol/dex contraindicated; **status epilepticus**; severe **alcohol/benzodiazepine withdrawal**; need for strong amnesia (e.g., distressed ECMO patient when other options limited).
**Typical dosing (adult):**
* **Bolus:** 1–2 mg IV q2–3 min to effect (caution with opioids).
* **Infusion:** **0.02–0.1 mg/kg/h** (i.e., **0.3–1.7 mcg/kg/min**); some units go up to **0.2 mg/kg/h** short-term.
* **Titrate to RASS target**; schedule sedation holds; prefer **days → hours**, not days → **weeks**.
**Status epilepticus (when using midazolam infusion):**
* **Bolus 0.1–0.2 mg/kg**, then **0.05–0.2 mg/kg/h**, titrate to seizure suppression (EEG guided). Expect tolerance → escalating rates; consider alternative agents if refractory.
---
# 4) Special populations — dosing cautions
## Pregnancy
* Crosses placenta → **neonatal respiratory depression/hypotonia** possible; avoid in **1st trimester** if alternatives exist.
* For urgent indications (e.g., seizure control), use **lowest effective dose**; have neonatal team ready.
## Lactation
* Small amounts in milk; **generally compatible** with breastfeeding after single procedural doses (often advise a short 4–6 h pause if large doses). Clinical judgment/local policy.
## Hepatic impairment
* **CYP3A metabolism** reduced → **lower dose & slower titration**; expect prolonged effect. Monitor sedation depth closely.
## Renal impairment
* **Active glucuronide metabolite accumulates** → **prolonged sedation** even when parent drug is low. Prefer non-benzo regimens for long sedation; if used, **reduce rate** and watch for delayed wake-up.
## Obesity
* Larger Vd → accumulation with boluses/infusions.
* **Bolus to Lean/Adjusted BW**, then titrate to effect; keep infusion **as low and brief as possible**.
## Paediatrics
* **Premed (oral):** **0.5 mg/kg** (max ~20 mg).
* **Intranasal/buccal:** **0.2–0.3 mg/kg** for anxiolysis/seizures.
* **IV sedation:** **0.02–0.05 mg/kg** boluses; **infusion 0.02–0.1 mg/kg/h**.
* Neonates/infants: increased sensitivity; prefer minimal dosing and careful monitoring.
---
# 5) Drug interactions (clinically key)
* **CNS depressants (opioids, propofol, volatiles, alcohol):** **synergistic** respiratory/CVS depression → **halve doses**, give slowly, secure airway/monitoring.
* **CYP3A4/5 inhibitors** (e.g., **azoles**, **macrolides/clarithro-**, **protease inhibitors**, **diltiazem/verapamil**, grapefruit): ↑ levels → **oversedation/apnoea**.
* **CYP3A inducers** (e.g., **rifampicin**, **carbamazepine**, **phenytoin**, **St John’s wort**): ↓ effect → higher needs.
* **Valproate** may potentiate sedation; watch depth.
* **Ketoconazole + midazolam** (IV) is a classic severe interaction—avoid.
---
# 6) Significant complications & what to do
* **Respiratory depression / apnoea** (esp. with opioids/propofol): airway readiness, titrate slowly, capnography.
* **Hypotension** in hypovolaemia/poor EF: pre-empt with fluids/pressor support; avoid large boluses.
* **Paradoxical agitation/disinhibition** (1–10%): stop midazolam; small **flumazenil** (below) or switch agent.
* **Delirium** with prolonged ICU use: favour non-benzo sedation; daily awakening.
* **Prolonged coma after stopping** in renal/hepatic impairment/obesity: anticipate, check metabolites, supportive care.
**Reversal (Flumazenil):**
* **0.2 mg IV** over 15 s; repeat **0.1–0.2 mg** every minute to effect (commonly up to **1 mg**; max **3–5 mg**).
* **Cautions:** may precipitate **seizures** in chronic benzo users/TCAs overdose; effect may **wear off before midazolam** → monitor for **re-sedation**.
---
## Pocket viva line
*Midazolam is a benzodiazepine **GABA-A PAM** that increases opening **frequency** (needs GABA). Fast onset, strong **amnesia**, good anticonvulsant—but accumulates with **renal/hepatic dysfunction/obesity** via active metabolite, interacts via **CYP3A**, and combined with opioids can cause **apnoea**. ICU infusions 0.02–0.1 mg/kg/h—keep short; prefer non-benzo sedation when possible.*
---
Want me to convert this into a **one-page printable card** (with infusion quick-math and interaction red-flags) for your ICU pocket? And what’s your **next drug**—**ketamine**, **dexmedetomidine**, or a vasoactive (e.g., **norepinephrine**) next?
